Clinical Trial Update: Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effects of PA-824 (pretomanid) alone and in combination with moxifloxacin on the QTc interval in healthy volunteers has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• PA-824 (pretomanid) (pretomanid)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED